CEACAM5 and colorectal carcinoma: In France, two multicentric prospective phase-I clinical studies are on-going, assessing pretargeted 177Lu-IMP288 (one injection) in patients with metastatic CEA-positive lung carcinoma and fractionated injection of 90Y-IMP288 in metastatic CRC patients.